AVBP News
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ArriVent BioPharma, Inc. (ArriVent or the Company) (NASDAQ: AVBP) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Business Wire
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ArriVent BioPharma, Inc. (ArriVent or the Company) (NASDAQ: AVBP) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Business Wire
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharmaPR NewswireNEW YORK, Oct. 7, 2026AVBP was down 56.7...
PR Newswire
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP) ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)PR NewswireNEW YORK, Oct. 6...
PR Newswire
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.read more...
Benzinga
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at Truist Financial
Truist Financial upgraded ArriVent BioPharma to a "strong-buy" rating in a research note on Monday...
MarketBeat
ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Monday
ArriVent BioPharma (NASDAQ:AVBP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-arrivent-biopharma-inc-stock...
MarketBeat
Noteworthy Thursday Option Activity: AVBP, VIAV, ASTS
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in ArriVent Biopharma Inc (Symbol: AVBP), where a total volume of 4,042 contracts has been traded thus far today, a contract volume which is representative of appro...
Nasdaq News: Markets
FY2026 Earnings Estimate for AVBP Issued By Lifesci Capital
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Equities researchers at Lifesci Capital dropped their FY2026 earnings per share estimates for ArriVent BioPharma in a report released on Monday, April 27th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of...
MarketBeat
Citigroup Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $45.00
Citigroup increased their target price on shares of ArriVent BioPharma from $33.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday...
MarketBeat